Wang Zhi-rong, Li Ding-guo, Chen Xi-mei, Huang Xin, Wei Hong-shan, Wang Yu-qin, Xu Qin-fang, Lu Han-ming
Department of Gastroenterology, Tongji Hospital, Tongji University, Shanghai 200065, China.
Zhonghua Gan Zang Bing Za Zhi. 2003 Jul;11(7):408-11.
To investigate the therapeutic effects and mechanism of octreotide on experimental hepatic fibrosis in rats.
Hepatofibrotic rats models were established with carbon tetrachloride. All the experimental rats were divided into four groups: normal control group, pre-and post-treatment model group, and octreotide-treated group in which the rats were injected subcutaneously with octreotide at the dose of 50ng/100g, twice daily, for thirty days. Serum levels of hyaluronic acid (HA), laminin (LN) and pro-collagen type III peptide (PCIII) were detected by radioimmunoassay. Hepatic fibrosis scoring grade was assessed through Van-Gieson staining and observed under light microscope. Protein expression levels of alpha-smooth muscle actin (alpha-SMA) and transforming growth factor beta1 (TGFbeta1) were determined with immunohistochemical staining method. Messenger RNA (mRNA) levels of collagen type I and PCIII were detected by reverse transcription polymerase chain reaction.
Serum levels of HA (ng/L), LN (microg/L) and PCIII (ng/L) in pre- and post-treatment model groups were higher than those in normal control group (121.8+/-9.5 and 110.3+/-13.4 vs. 33.1+/-3.7, 85.7+/-12.1 and 78.2+/-7.9 vs. 37.1+/-6.3, 35.9+/-3.5 and 33.7+/-2.6 vs. 15.6+/-2.8, respectively, t > or = 9.41, P<0.05), and there was no significant difference between the two model groups. Concentrations of HA (55.8ng/L+/-7.2ng/L), LN (43.1microg/L+/-3.4microg/L) and PCIII (27.8ng/L+/-3.4ng/L) decreased significantly in octreotide-treated group, compared with those in model groups (t >or=2.76, P<0.05). With histological analysis, fibrotic scoring grade in octreotide-treated group was obviously ameliorated, compared with that in model groups (chi2 > or = 3.97, P<0.05). Imaging analysis revealed that alpha-SMA and TGFbeta1 immunohistological staining areas were markedly shrinked in octreotide-treated group (t > or = 2.47, P < 0.05). In two model groups, PCIII and type I mRNA levels significantly up-regulated as compared with those in normal group (t > or = 9.27, P<0.001), and they were inhibited by octreotide markedly (t > or = 2.47, P<0.05).
Octreotide can inhibit hepatic stellate cells transforming into myofibroblasts, down-regulate TGFbeta1, collagen type I and PCIII transcriptions, so that it has therapeutic effects on experimental hepatic fibrosis.
探讨奥曲肽对大鼠实验性肝纤维化的治疗作用及机制。
采用四氯化碳建立肝纤维化大鼠模型。将所有实验大鼠分为四组:正常对照组、治疗前后模型组、奥曲肽治疗组,奥曲肽治疗组大鼠皮下注射奥曲肽,剂量为50ng/100g,每日两次,共30天。采用放射免疫分析法检测血清透明质酸(HA)、层粘连蛋白(LN)和III型前胶原肽(PCIII)水平。通过Van-Gieson染色评估肝纤维化评分等级,并在光学显微镜下观察。采用免疫组织化学染色法测定α-平滑肌肌动蛋白(α-SMA)和转化生长因子β1(TGFβ1)的蛋白表达水平。通过逆转录聚合酶链反应检测I型胶原和PCIII的信使核糖核酸(mRNA)水平。
治疗前后模型组血清HA(ng/L)、LN(μg/L)和PCIII(ng/L)水平高于正常对照组(分别为121.8±9.5和110.3±13.4 vs. 33.1±3.7,85.7±12.1和78.2±7.9 vs. 37.1±6.3,35.9±3.5和33.7±2.6 vs. 15.6±2.8,t≥9.41,P<0.05),两个模型组之间无显著差异。与模型组相比,奥曲肽治疗组HA(55.8ng/L±7.2ng/L)、LN(43.1μg/L±3.4μg/L)和PCIII(27.8ng/L±3.4ng/L)浓度显著降低(t≥2.76,P<0.05)。组织学分析显示,与模型组相比,奥曲肽治疗组纤维化评分等级明显改善(χ2≥3.97,P<0.05)。影像学分析显示,奥曲肽治疗组α-SMA和TGFβ1免疫组织化学染色面积明显缩小(t≥2.47,P<0.05)。在两个模型组中,与正常组相比,PCIII和I型mRNA水平显著上调(t≥9.27,P<0.001),且奥曲肽显著抑制了它们(t≥2.47,P<0.05)。
奥曲肽可抑制肝星状细胞向肌成纤维细胞转化,下调TGFβ1、I型胶原和PCIII转录,从而对实验性肝纤维化具有治疗作用。